MedTrace Logo

Myovista vs NT Pro-BNP Heart Failure Referral Tool

NCT05068154 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2021-10-05

No results posted yet for this study

Summary

It is hypothesised that the MyoVista wavECG has the potential to show non inferior sensitivity and specificity compared to the current heart failure pathway screening tools of BNP/NT-proBNP and 12 lead resting ECG, but has the advantage of providing a single, familiar, inexpensive point of care test which provides point of care results and can act as a prescreen, or in circumstances replacement to BNP/NTpro-BNP testing, and eliminate a proportion of the unnecessary testing and echo referrals.

A comparative performance analysis of the modalities will form the basis for the study with subsequent reporting on the financial impact and societal benefits of any potential pathway change.

Conditions

Interventions

DIAGNOSTIC_TEST

Myovista® WavECG™

The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities

Sponsors & Collaborators

  • Royal Cornwall Hospitals Trust

    collaborator OTHER

  • Northern Care Alliance NHS Foundation Trust

    collaborator OTHER

  • North Tees and Hartlepool NHS Foundation Trust

    collaborator OTHER

  • Riverside Medical Center

    collaborator OTHER

  • HeartSciences Inc, USA

    collaborator UNKNOWN

  • Great Western Hospitals NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-05-31
Completion
2024-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05068154 on ClinicalTrials.gov